Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -155.23% | -121.46% | -215.64% | -135.85% | 345.29% |
| Total Depreciation and Amortization | 18.88% | 39.81% | 54.24% | 47.39% | 31.98% |
| Total Amortization of Deferred Charges | 300.00% | -- | 200.00% | 0.00% | -66.67% |
| Total Other Non-Cash Items | 574.26% | 291.25% | 397.72% | 240.24% | -4,364.77% |
| Change in Net Operating Assets | -155.59% | -27.51% | 67.82% | 0.24% | -74.41% |
| Cash from Operations | 628.73% | 330.46% | 338.26% | 891.32% | 120.77% |
| Capital Expenditure | 32.96% | -100.72% | -35.27% | -213.00% | 71.85% |
| Sale of Property, Plant, and Equipment | 618.95% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Investing | 61.39% | -196.42% | -117.50% | -357.31% | 56.17% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | -505.40% | -27.86% | 91.39% | 92.64% | 93.74% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -502.96% | -124.73% | 87.56% | 89.39% | 87.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,164.77% | 699.59% | 120.70% | 109.33% | 93.95% |